InstalabLoading...
InstalabLoading...
A genetic variant in the gene that controls lipoprotein(a) production, signaling a lifelong predisposition to elevated cardiovascular risk.
If you carry this variant, your body has been producing unusually high levels of a cholesterol-rich particle called lipoprotein(a) since birth. Unlike standard cholesterol, which responds dramatically to diet and medication, lipoprotein(a) is largely set by your DNA. That makes this genetic test uniquely valuable: it tells you something a standard lipid panel cannot, and it only needs to be done once.
The variant known as rs10455872 sits in the LPA gene (lipoprotein A), which encodes the protein backbone of the lipoprotein(a) particle. Carrying one or two copies of the risk version (the G allele) is one of the strongest known genetic drivers of high Lp(a) levels, pushing them roughly 5 to 20 times higher than non-carriers. Each copy of the G allele raises your Lp(a) by about 0.91 standard deviations above the population average.
Why does that matter? Lipoprotein(a) is a sticky, inflammatory particle that accelerates plaque buildup in your arteries. Elevated levels are causally linked to coronary artery disease, aortic valve calcification, peripheral artery disease, and abdominal aortic aneurysm. The American Heart Association now recommends that every adult have their Lp(a) measured at least once, especially if there is a personal or family history of early heart disease.
This test reports one of three possible genotypes. Each tells you how many copies of the risk allele you carry and what that implies for your Lp(a) levels and cardiovascular risk.
If you carry at least one G allele, the most important next step is getting your actual Lp(a) concentration measured through a blood test. The genetic variant tells you that your levels are very likely elevated; the blood test tells you by how much.
The connection between this variant and heart disease is among the most robust in cardiovascular genetics. A meta-analysis of over 55,000 people found that carrying the G allele raised coronary heart disease risk with an odds ratio between 1.61 and 1.75. But the risk extends well beyond the coronary arteries.
This variant is especially notable for its link to calcific aortic valve disease, a condition where calcium deposits gradually stiffen the aortic valve and restrict blood flow from the heart. It is the only common genetic variant that has reached genome-wide significance as a risk factor for this condition. A systematic review and meta-analysis found an odds ratio of 1.42 for aortic valve calcification among carriers. The association is strongest in younger adults (ages 55 to 64) and becomes weaker with advancing age.
For people who already have some degree of aortic stenosis, elevated Lp(a) appears to accelerate disease progression. Those with high Lp(a) showed faster increases in peak aortic jet velocity (0.26 versus 0.17 meters per second per year) and were more likely to need valve replacement.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| Over 55,000 participants across multiple studies | Coronary heart disease risk in G allele carriers versus non-carriers | Carriers were roughly 1.6 to 1.75 times more likely to develop coronary heart disease |
| Large pooled analysis of aortic valve disease studies | Risk of calcific aortic valve disease in carriers versus non-carriers | Carriers had about 1.4 times higher risk of aortic valve calcification |
| Population-based study of peripheral artery outcomes | Risk of peripheral artery disease and limb events in those with elevated Lp(a) | About 1.45 times higher risk of lower-extremity amputation |
| Adults with pre-existing aortic stenosis | Aortic valve disease progression by Lp(a) level | Those with elevated Lp(a) had faster valve narrowing and more frequent valve replacement |
Sources: Li et al. meta-analysis (coronary heart disease); Pantelidis et al. meta-analysis (aortic valve disease); Thomas et al. (peripheral artery disease); Capoulade et al. (aortic stenosis progression).
What this means for you: if you carry one or two G alleles, you have a genetically elevated baseline risk for arterial disease and valve calcification that standard risk calculators do not capture. This information can change the intensity of your preventive strategy, particularly around LDL cholesterol management and monitoring for valve disease.
The frequency of the rs10455872 risk allele varies substantially across populations, and so does its predictive value.
This is an important caveat. If you are not of European descent and your rs10455872 result comes back negative (A/A), that does not mean your Lp(a) is normal. A direct blood measurement of Lp(a) concentration is essential regardless of your genetic result, especially in populations where this SNP is uncommon.
Because Lp(a) levels are overwhelmingly determined by genetics, the interventions that dramatically lower LDL cholesterol (diet, exercise, statins) have minimal effect on Lp(a). Statins, in fact, may slightly raise Lp(a) levels, though they remain essential for overall cardiovascular risk reduction in carriers. The focus for rs10455872 carriers is on therapies that either directly lower Lp(a) or aggressively reduce other modifiable risk factors.
Medications available now:
Therapies in clinical trials:
Several drugs in advanced clinical trials specifically target Lp(a) production in the liver. Pelacarsen, an antisense therapy, reduces Lp(a) by up to 80% and is being tested in the phase 3 Lp(a)HORIZON trial. Two small interfering RNA therapies, olpasiran and SLN360, have shown reductions of up to 98% in earlier-phase trials and are progressing through phase 3 studies. These represent a potential shift from managing around high Lp(a) to directly eliminating the excess.
Because you cannot yet eliminate elevated Lp(a) with currently available treatments, the standard approach for carriers is aggressive management of every other cardiovascular risk factor you can control: LDL cholesterol, blood pressure, blood sugar, smoking, and body composition. Think of it as compensating for a risk factor you were born with by being especially diligent about the ones you can change.